Peripheral T-cell lymphomas: diagnosis and management - PubMed (original) (raw)
Review
Peripheral T-cell lymphomas: diagnosis and management
Claire E Dearden et al. Hematol Oncol Clin North Am. 2003 Dec.
Abstract
Peripheral T-cell lymphomas are a diverse group of diseases with varying clinical manifestations. Response to conventional chemotherapy generally is poor. Treatment using purine analogs has achieved response rates between 25% and 60% in relapsed/refractory patients, with minimal toxicity. The highest response rates were seen with pentostatin and gemcitabine. Using purine analogs in combination therapy may improve response rates, albeit with an increased risk of toxicity. The role of purine analogs as first line therapy in patients who have otherwise favorable prognostic factors has not been defined. Monoclonal antibody therapy has emerged in the last decade as a promising approach in treating T-cell malignancies. Campath-1H is an effective and well-tolerated therapy in these diseases. Durable remissions have been seen in heavily pretreated patients and in up to two thirds of patients who had T-PLL, which is the largest disease group studied. These results in T-PLL are significantly better than those reported with other therapies; this suggests that Campath-1H should be moved to first line therapy in this aggressive disease. The way in which monoclonal antibodies work indicate that they may be particularly useful in treating patients who have minimal residual disease, and, in this setting, facilitate stem cell transplantation. In addition, the activity of Campath-1H to deplete T cells has been exploited in preparative regimens before allogeneic bone marrow transplantation. These approaches may be worth further investigation in patients who have T-cell lymphomas. None of the therapies that are available to treat the mature T-cell neoplasms seems to be curative, other than in selected patients who have favorable ALCL. Much of the data have been drawn from small, non-randomized studies. There is a need for larger, prospective, randomized trials to examine these novel therapies and to further explore combination regimens, which may exploit potential synergism.
Similar articles
- Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
Shustov A. Shustov A. Best Pract Res Clin Haematol. 2013 Mar;26(1):89-99. doi: 10.1016/j.beha.2013.04.008. Epub 2013 May 25. Best Pract Res Clin Haematol. 2013. PMID: 23768643 Review. - Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
Pawson R, Dyer MJ, Barge R, Matutes E, Thornton PD, Emmett E, Kluin-Nelemans JC, Fibbe WE, Willemze R, Catovsky D. Pawson R, et al. J Clin Oncol. 1997 Jul;15(7):2667-72. doi: 10.1200/JCO.1997.15.7.2667. J Clin Oncol. 1997. PMID: 9215839 Clinical Trial. - Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
Coiffier B, Federico M, Caballero D, Dearden C, Morschhauser F, Jäger U, Trümper L, Zucca E, Gomes da Silva M, Pettengell R, Weidmann E, d'Amore F, Tilly H, Zinzani PL. Coiffier B, et al. Cancer Treat Rev. 2014 Oct;40(9):1080-8. doi: 10.1016/j.ctrv.2014.08.001. Epub 2014 Aug 24. Cancer Treat Rev. 2014. PMID: 25199959 Review. - The role of high-dose therapy in peripheral T-cell lymphomas.
Reimer P, Rüdiger T, Wilhelm M. Reimer P, et al. Clin Lymphoma Myeloma. 2006 Mar;6(5):373-9. doi: 10.3816/CLM.2006.n.012. Clin Lymphoma Myeloma. 2006. PMID: 16640812 Review. - Alemtuzumab in peripheral T-cell malignancies.
Dearden C. Dearden C. Cancer Biother Radiopharm. 2004 Aug;19(4):391-8. doi: 10.1089/cbr.2004.19.391. Cancer Biother Radiopharm. 2004. PMID: 15453953 Review.
Cited by
- [Comparison of allogeneic or autologous hematopoietic stem cell transplant for high-risk peripheral T cell lymphomas].
Wang QL, Huang HW, Jin ZM, Tang XW, Qiu HY, Fu CC, Han Y, Miao M, Chang HR, Sun AN, Wu DP. Wang QL, et al. Zhonghua Xue Ye Xue Za Zhi. 2016 Nov 14;37(11):952-956. doi: 10.3760/cma.j.issn.0253-2727.2016.11.005. Zhonghua Xue Ye Xue Za Zhi. 2016. PMID: 27995879 Free PMC article. Chinese. - Denileukin Diftitox (Ontak) as Maintenance Therapy for Peripheral T-Cell Lymphomas: Three Cases with Sustained Remission.
Fuentes AC, Szwed E, Spears CD, Thaper S, Dang LH, Dang NH. Fuentes AC, et al. Case Rep Oncol Med. 2015;2015:123756. doi: 10.1155/2015/123756. Epub 2015 Jul 9. Case Rep Oncol Med. 2015. PMID: 26240767 Free PMC article. - Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.
Dong M, He XH, Liu P, Qin Y, Yang JL, Zhou SY, Yang S, Zhang CG, Gui L, Zhou LQ, Shi YK. Dong M, et al. Med Oncol. 2013 Mar;30(1):351. doi: 10.1007/s12032-012-0351-4. Epub 2012 Dec 27. Med Oncol. 2013. PMID: 23269584 - Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S. O'Connor OA, et al. J Clin Oncol. 2011 Mar 20;29(9):1182-9. doi: 10.1200/JCO.2010.29.9024. Epub 2011 Jan 18. J Clin Oncol. 2011. PMID: 21245435 Free PMC article. Clinical Trial. - Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Ravandi F, et al. J Clin Oncol. 2009 Nov 10;27(32):5425-30. doi: 10.1200/JCO.2009.22.6688. Epub 2009 Oct 5. J Clin Oncol. 2009. PMID: 19805674 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources